ArticleInternational ophthalmology2025
Treatment of ocular sarcoidosis. Study of 65 patients from a series of 342 from a university hospital in northern Spain.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesOcular involvement in sarcoidosis is a relatively frequent manifestation causing potentially severe complications. Our aim was to evaluate visual outcomes and treatment in a cohort of patients diagnosed with ocular sarcoidosis.
methodsWe conducted a retrospective study of a cohort of 342 patients diagnosed with sarcoidosis according the ATS criteria (compatible clinical, radiological and pathological presentation excluding other granulomatous diseases) from January 1999 to December 2019 in a single university hospital. Ocular manifestations and systemic treatments were assessed: systemic glucocorticoids (GC), conventional synthetic immunosuppressive (csIS) drugs and biological therapy (BT). Best corrected visual acuity (BCVA) according to the different systemic treatments used was compared at diagnosis and after one-year follow-up.
resultsOcular sarcoidosis was observed in 65 of 342 (19%). Main ocular manifestations were uveitis (54; 83.1%), orbital lesions (5; 7.7%), retinal vasculitis (4; 6.2%), dry eye (4; 6.2%) and scleritis (1; 1.5%). Systemic treatment with GC was used in 52 (80%) patients, csIS in 32 (49.2%) and BT in 17 (26.2%) patients. BT was most used in panuveitis (62.5%), posterior uveitis (60%), intermediate uveitis (50%) and retinal vasculitis (50%). Median BCVA at diagnosis was 0.6 [IQR: 0.3-0.8] and 0.9 [0.6-1] at one year later, no significant differences in BCVA were observed between systemic therapies.
conclusionsIn conclusion severe manifestations, like Panuveitis, posterior uveitis, intermediate uveitis and retinal vasculitis required an aggressive treatment. In uveitis, a significant improvement in BCVA was observed after one year of follow-up.
Indexed as
Identifiers
40576841What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.